Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Trading 9% Higher – Here’s Why

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) rose 9% during mid-day trading on Tuesday . The stock traded as high as $0.4129 and last traded at $0.3870. 156,252 shares were traded during mid-day trading, a decline of 47% from the average session volume of 294,953 shares. The stock had previously closed at $0.3552.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Trading Down 6.2%

The stock has a fifty day moving average of $0.45 and a two-hundred day moving average of $0.61.

Institutional Trading of Hong Kong Pharma Digital Technology

An institutional investor recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. acquired a new position in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned about 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the SEC.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.